EMA Favors Giving Amylyx’s AMX0035 Orphan Medicine Status for ALS
A branch of the European Medicines Agency (EMA) has recommended that Amylyx‘s investigational oral compound AMX0035 be designated an orphan medicine to treat people with amyotrophic lateral sclerosis (ALS). Orphan designation is given to medicines in Europe with the potential to be safe…